Cargando…
Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease
PURPOSE: To estimate the risk of dyskinesia and impulse control disorders (ICDs) in patients with Parkinson's disease (PD) prescribed ropinirole prolonged‐release (R‐PR) compared to those prescribed immediate‐release dopamine agonists (IR‐DA) as monotherapy. METHODS: PD patients initiating R‐PR...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317950/ https://www.ncbi.nlm.nih.gov/pubmed/32153056 http://dx.doi.org/10.1002/pds.4986 |
_version_ | 1783550745707020288 |
---|---|
author | Gungabissoon, Usha Kirichek, Oksana El Baou, Céline Galwey, Nicholas |
author_facet | Gungabissoon, Usha Kirichek, Oksana El Baou, Céline Galwey, Nicholas |
author_sort | Gungabissoon, Usha |
collection | PubMed |
description | PURPOSE: To estimate the risk of dyskinesia and impulse control disorders (ICDs) in patients with Parkinson's disease (PD) prescribed ropinirole prolonged‐release (R‐PR) compared to those prescribed immediate‐release dopamine agonists (IR‐DA) as monotherapy. METHODS: PD patients initiating R‐PR or IR‐DA as monotherapy between 2008 and 2013 were identified on the Clinical Practice Research Datalink. The cohorts were propensity score matched on a 1:1 basis. The incidence of dyskinesia and ICD in each treatment cohort and the incidence rate ratios were calculated. Adherence to medication and time to levodopa initiation were also evaluated. RESULTS: We identified 341 patients in each treatment cohort after propensity score matching. The baseline characteristics were generally comparable. Dyskinesia incidence in R‐PR and IR‐DA cohorts was 2.98 (95% CI: 0.74‐11.9) and 3.93 (95% CI: 0.98‐15.7) per 1000 person‐years, respectively (incidence rate ratio of R‐PR vs ID‐DA: 0.76, 95% CI: 0.11‐5.38). Less than five cases of ICD were identified and all occurred in the IR‐DA cohort. The patients in the R‐PR cohort remained on treatment for a significantly longer duration than those in the IR‐DA cohort (682 days vs 444 days; P < .0001) and had greater adherence to the medication. The median time to levodopa initiation was 417 days (IQR: 205‐736) in R‐PR vs 297 days (IQR: 111‐552) in IR‐DA cohort. CONCLUSIONS: The number of dyskinesia and ICD events was lower than expected, resulting in an underpowered study. A significantly longer persistence and greater adherence to medication was observed in patients receiving R‐PR compared to IR‐DA. |
format | Online Article Text |
id | pubmed-7317950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73179502020-06-29 Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease Gungabissoon, Usha Kirichek, Oksana El Baou, Céline Galwey, Nicholas Pharmacoepidemiol Drug Saf Original Reports PURPOSE: To estimate the risk of dyskinesia and impulse control disorders (ICDs) in patients with Parkinson's disease (PD) prescribed ropinirole prolonged‐release (R‐PR) compared to those prescribed immediate‐release dopamine agonists (IR‐DA) as monotherapy. METHODS: PD patients initiating R‐PR or IR‐DA as monotherapy between 2008 and 2013 were identified on the Clinical Practice Research Datalink. The cohorts were propensity score matched on a 1:1 basis. The incidence of dyskinesia and ICD in each treatment cohort and the incidence rate ratios were calculated. Adherence to medication and time to levodopa initiation were also evaluated. RESULTS: We identified 341 patients in each treatment cohort after propensity score matching. The baseline characteristics were generally comparable. Dyskinesia incidence in R‐PR and IR‐DA cohorts was 2.98 (95% CI: 0.74‐11.9) and 3.93 (95% CI: 0.98‐15.7) per 1000 person‐years, respectively (incidence rate ratio of R‐PR vs ID‐DA: 0.76, 95% CI: 0.11‐5.38). Less than five cases of ICD were identified and all occurred in the IR‐DA cohort. The patients in the R‐PR cohort remained on treatment for a significantly longer duration than those in the IR‐DA cohort (682 days vs 444 days; P < .0001) and had greater adherence to the medication. The median time to levodopa initiation was 417 days (IQR: 205‐736) in R‐PR vs 297 days (IQR: 111‐552) in IR‐DA cohort. CONCLUSIONS: The number of dyskinesia and ICD events was lower than expected, resulting in an underpowered study. A significantly longer persistence and greater adherence to medication was observed in patients receiving R‐PR compared to IR‐DA. John Wiley & Sons, Inc. 2020-03-09 2020-05 /pmc/articles/PMC7317950/ /pubmed/32153056 http://dx.doi.org/10.1002/pds.4986 Text en © 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Reports Gungabissoon, Usha Kirichek, Oksana El Baou, Céline Galwey, Nicholas Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease |
title | Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease |
title_full | Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease |
title_fullStr | Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease |
title_full_unstemmed | Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease |
title_short | Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease |
title_sort | comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with parkinson's disease |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317950/ https://www.ncbi.nlm.nih.gov/pubmed/32153056 http://dx.doi.org/10.1002/pds.4986 |
work_keys_str_mv | AT gungabissoonusha comparisonoflongtermuseofprolongedreleaseropiniroleandimmediatereleasedopamineagonistsinanobservationalstudyinpatientswithparkinsonsdisease AT kirichekoksana comparisonoflongtermuseofprolongedreleaseropiniroleandimmediatereleasedopamineagonistsinanobservationalstudyinpatientswithparkinsonsdisease AT elbaouceline comparisonoflongtermuseofprolongedreleaseropiniroleandimmediatereleasedopamineagonistsinanobservationalstudyinpatientswithparkinsonsdisease AT galweynicholas comparisonoflongtermuseofprolongedreleaseropiniroleandimmediatereleasedopamineagonistsinanobservationalstudyinpatientswithparkinsonsdisease |